Tumours, which lose MHC expression or acquire upstream defects in antigen presentation, will be relatively resistant to immune‐mediated elimination by tumour‐specific T‐cells, resulting in impaired activation of CD4+ (MHC‐II recognition) and CD8+ T‐cells (MHC‐I recognition). This evidence concerns the gene HLA-C and neoplasm.